Agenda: Alzheimer's Disease Research Summit 2012

'Alzheimer's Disease Research Summit 2012; Path to Treatment and Prevention. May 14-15, 2012, National Instittutes of Health, Bethesda, MD.'

May 14-15, 2012
Natcher Auditorium, NIH Campus
Bethesda, MD

May 14, 2012

7:00am-8:00 am:  Registration

8:00am-8:30am

Introductory Remarks
Richard Hodes, MD, Director, National Institute on Aging
Francis Collins, MD, PhD, Director, National Institutes of Health

8:30am-9:00am

Plenary Lecture:
The Growing Social and Economic Impact of Dementia in the United States: A Perfect Storm?
Ken Langa, MD, PhD, University of Michigan

9:00am -11:30am

Session 1: Interdisciplinary Approach to Discovering and Validating the Next Generation of Therapeutic Targets for Alzheimer’s Disease

Session Chairs:
Michael Hutton, PhD, Eli Lilly
Lennart Mucke, MD, Gladstone Institute of Neurological Disease

9:00am -9:05am
Charge to the session: Michael Hutton, PhD, Eli Lilly

9:05am-9:20am
Stephen Friend, MD, PhD, Sage Bionetworks

9:20am-9:35am
Richard Morimoto, PhD, Northwestern University

9:35am-9:50am
Lennart Mucke, MD, Gladstone Institute of Neurological Disease

9:50am-10:30am
Discussants’ Highlights:
John Hardy, PhD, University College London
Richard Mayeux, MD, Columbia University
Lenore Launer, PhD, National Institute on Aging
Roberta Diaz Brinton, PhD, University of Southern California
Rima Kaddurah-Daouk, PhD, Duke University
Dennis Selkoe, MD, Harvard Medical School
William Potter, MD, PhD, Consultant

10:30am-11:30am
Open Discussion

11:30-12:45pm: Lunch

12:45pm -3:00pm

Session 2: Challenges in Preclinical Therapy Development

Session Chair:
Barry Greenberg, PhD, Toronto Dementia Research Alliance

12:45pm-12:50pm
Charge to the Session: Barry Greenberg, PhD, Toronto Dementia Research Alliance

12:50pm-1:05pm
Christopher Lipinski, PhD, Consultant

1:05pm-1:25pm
Barry Greenberg, PhD, Toronto Dementia Research Alliance

1:25pm-1:40pm
Piet van der Graaf, PhD, Pfizer/Neusentis

1:40pm-2:10pm
Discussants’ Highlights:
Peter Lansbury, PhD, Harvard Medical School
Frank Longo, MD, PhD, Stanford University
Kelly Bales, PhD, Pfizer
Eliezer Masliah, MD, University of California, San Diego
Steven Perrin, PhD, ALS Therapy Development Institute
Richard Mohs, PhD, Eli Lilly

2:10pm-3:05pm
Open Discussion

3:05pm-5:50pm

Session 3: Who to Treat, When to Treat, and What Outcomes to Measure

Session Chairs:
Paul Aisen, MD, University of California, San Diego
Reisa Sperling MD, Harvard Medical School

3:05pm-3:10pm
Charge to the Session: Paul Aisen, MD, University of California, San Diego

3:10pm-3:25pm
Paul Aisen, MD, University of California, San Diego

3:25pm-3:40pm
Eric Siemers, MD, Eli Lilly

3:40pm-3:55pm
Reisa Sperling, MD, Harvard Medical School

3:55pm-4:10pm
Russell Katz, MD, US Food and Drug Administration

4:10pm-4:50pm
Discussants’ Highlights:
David Bennett, MD, Rush University
Eric Reiman, MD, Banner Alzheimer Institute
Jennifer Manly, PhD, Columbia University
Nick Fox, MD, University College London
Clifford Jack, MD, PhD, Mayo Clinic
Ronald Petersen, MD, PhD, Mayo Clinic
David Holtzman, MD, Washington University
John Trojanowski, MD, University of Pennsylvania

4:50pm-5:50pm
Open Discussion

May 15, 2012

7:30am-8:00am: Registration

8:00am-9:50am  

Session 4: Drug Repurposing and Combinatorial Therapy

Session Chair:
Suzanne Craft, PhD, University of Washington

8:00am-8:05am
Charge to the Session: Suzanne Craft, PhD, University of Washington

8:05am-8:20 am
Donald Frail, PhD, Astra Zeneca

8:20am-8:35am
Linda Brady, PhD, National Institute of Mental Health

8:35am-8:50am
Malcolm Young, PhD, e-Therapeutics

8:50am-9:15am
Discussants’ Highlights

Mary Sano, PhD, Mount Sinai School of Medicine
Constantine Lyketsos, MD, Johns Hopkins University
Eric Larson, MD, Group Health Research Institute
Christopher Lipinski, PhD, Consultant
Dale Bredesen, MD, Buck Institute

9:15am-9:50am
Open Discussion

9:50am-10:30am

Session 5: Non-Pharmacological Interventions

Session Chair:
Carl Cotman, PhD, University of California, Irvine

9:50am-9:55am
Charge to the Session: Carl Cotman, PhD, University of California, Irvine

9:55am-10:10am
Elizabeth Head, PhD, University of Kentucky

10:10am-10:25am
Kirk Erickson, PhD, University of Pittsburgh

10:30am-11:05am

Taking Action--The National Plan to Address Alzheimer's Disease

Remarks by Kathleen Sebelius, Secretary, U.S. Department of Health and Human Services

11:05am-12:00pm

Session 5: Non-Pharmacological Interventions - Continued

11:05am -11:30am
Discussants’ Highlights

Mary Ganguli, MD, MPH, University of Pittsburgh
Jeffrey Burns, MD, University of Kansas
David Loewenstein, PhD, University of Miami
Laura Gitlin, PhD, Johns Hopkins University
Jeff Williamson, MD, Wake Forest University

11:30am – 12:00pm
Open Discussion

12:00pm-1:40pm

Session 6: New Models of Public Private Partnerships

Session Chair:
Howard Fillit, MD, Alzheimer’s Drug Discovery Foundation

12:00pm-12:05pm
Charge to the Session: Howard Fillit, MD, Alzheimer’s Drug Discovery Foundation

12:05pm-12:20pm
Barbara Mittleman, MD, NIH Public Private Partnership Program

12:20pm-12:35pm
Todd Sherer, PhD, Michael J Fox Foundation

12:35pm-12:50pm
Chas Bountra, PhD, University of Oxford

12:50pm-1:15pm
Discussants’ Highlights

Holly Soares, PhD, Bristol Myers Squibb
Johan Luthman, DDS, PhD, Merck
Collin Sandercock, JD, Perkins Coie LLP
Maria Carrillo, PhD, Alzheimer’s Association
Stephen Friend, MD, PhD, Sage Bionetworks

1:15pm-1:40pm
Open Discussion

2:00-3:30 pm

Executive Session

Session Chair:
Steven T. DeKosky, MD

Invitation only